Related Experiment Video
Updated: May 18, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors
Luqman Sulaiman1, Felix Haglund, Jamileh Hashemi
1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. Luqman.Sulaiman@ki.se
Abstract:
Mutations in the hyperparathyroidism type 2 (HRPT2/CDC73) gene and alterations in the parafibromin protein have been established in the majority of parathyroid carcinomas and in subsets of parathyroid adenomas. While it is known that CDC73-mutated parathyroid tumors display specific gene expression changes compared to CDC73 wild-type cases, the molecular cytogenetic profile in CDC73-mutated cases compared to unselected adenomas (with an expected very low frequency of CDC73 mutations) remains unknown. For this purpose, nine parathyroid tumors with established CDC73 gene inactivating mutations (three carcinomas, one atypical adenoma and five adenomas) were analyzed for copy number alterations and loss of heterozygosity using array-comparative genomic hybridization (a-CGH) and single nucleotide polymorphism (SNP) microarrays, respectively. Furthermore, CDC73 gene promoter methylation levels were assessed using bisulfite Pyrosequencing. The panel included seven tumors with single mutation and three with double mutations of the CDC73 gene. The carcinomas displayed copy number alterations in agreement with previous studies, whereas the CDC73-mutated adenomas did not display the same pattern of alterations at loci frequently deleted in unselected parathyroid tumors. Furthermore, gross losses of chromosomal material at 1p and 13 were significantly (p = 0.012) associated with parathyroid carcinomas as opposed to adenomas. Quantitative PCR-based copy number loss regarding CDC73 was observed in three adenomas, while all the carcinomas were diploid or showed copy number gain for CDC73 gene. Hypermethylation of the CDC73 gene promoter was not observed. Our data could suggest that CDC73-mutated parathyroid adenomas exhibit a partly unique cytogenetic profile in addition to that of carcinomas and unselected adenomas. Furthermore, CDC73-mutated carcinomas displayed losses at 1p and 13 which are not seen in CDC73-mutated adenomas, making these regions of interest for further studies regarding malignant properties in tumors from CDC73-mutated cases. However, due to the small sample size, validation of the results in a larger cohort is warranted.
Insights
Mutations in the HRPT2/CDC73 gene are linked to parathyroid tumors. CDC73-mutated parathyroid adenomas show a unique cytogenetic profile distinct from carcinomas and unselected adenomas.
Area of Science:
- Endocrinology
- Oncology
- Molecular Genetics
Background:
- Mutations in the HRPT2/CDC73 gene and parafibromin protein alterations are common in parathyroid carcinomas and some adenomas.
- CDC73-mutated parathyroid tumors exhibit distinct gene expression profiles compared to wild-type cases.
- The molecular cytogenetic profile of CDC73-mutated parathyroid tumors, particularly adenomas, remains largely uncharacterized.
Purpose of the Study:
- To investigate the molecular cytogenetic profile of parathyroid tumors with HRPT2/CDC73 gene mutations.
- To compare the genomic alterations and promoter methylation status in CDC73-mutated parathyroid carcinomas and adenomas.
- To identify potential cytogenetic differences between CDC73-mutated adenomas, carcinomas, and unselected parathyroid tumors.
Main Methods:
- Analysis of nine parathyroid tumors with confirmed CDC73 gene inactivating mutations (3 carcinomas, 1 atypical adenoma, 5 adenomas).
- Utilized array-comparative genomic hybridization (a-CGH) and single nucleotide polymorphism (SNP) microarrays for copy number alterations and loss of heterozygosity.
- Assessed CDC73 gene promoter methylation using bisulfite Pyrosequencing and quantitative PCR.
Main Results:
- Parathyroid carcinomas showed copy number alterations consistent with previous studies.
- CDC73-mutated adenomas did not exhibit the same deletion patterns as unselected adenomas.
- Significant association (p=0.012) of gross chromosomal losses at 1p and 13 with parathyroid carcinomas compared to adenomas.
- CDC73 gene copy number loss observed in three adenomas; carcinomas were diploid or had copy number gain.
- No hypermethylation of the CDC73 gene promoter was detected.
Conclusions:
- CDC73-mutated parathyroid adenomas possess a distinct cytogenetic profile separate from carcinomas and unselected adenomas.
- Losses at chromosomal regions 1p and 13 are characteristic of CDC73-mutated carcinomas, suggesting their role in malignant progression.
- Further validation in larger cohorts is necessary to confirm these findings and their clinical implications.
Related Concept Videos
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...

